Literature DB >> 32146458

Conservative treatment of early-onset tubercular periprosthetic joint infection following total knee arthroplasty.

Stefano Congia1, Gianfranco Puddu2, Giulio Sorrentino3, Giuseppe Dessì4, Giuseppe Marongiu5.   

Abstract

Tubercular periprosthetic joint infections (PJI) are uncommon diseases in developed countries. Therefore, the systematic screening for Mycobacterium tuberculosis (TB) is not currently recommended before a total knee arthroplasty procedure. However, due to the new human migration flows and higher mycobacterial infection rates, tuberculosis could represent a rare but potential cause for PJI. Controversies about tubercular PJI diagnosis, management and treatment   still exist due to a lack of clinical evidence. In the current report we present the case of an early-onset M. tuberculosis PJI of the knee and its successful conservative treatment with two years follow-up. Copyright (c) 2020 Stefano Congia, Gianfranco Puddu, Giulio Sorrentino, Giuseppe Dessì, Giuseppe Marongiu.

Entities:  

Keywords:  Mycobacterium tuberculosis; extrapulmonary tuberculosis; musculoskeletal tuberculosis; periprosthetic joint infection; revision surgery; total knee arthroplasty

Mesh:

Substances:

Year:  2020        PMID: 32146458     DOI: 10.3855/jidc.12053

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  2 in total

1.  Two-stage revision for treatment of tuberculous prosthetic hip infection: an outcome analysis.

Authors:  Tuan Van Le; Tran Binh Duong; Kha Quang Hien; Quyen Nguyen Quang Ton; Tan Huyn; Tran Phuoc Binh; Dao Thanh Tu; Pham Phuoc Tho; Le Nguyen Binh; Huynh Phuoc Hau; Truong Nguyen Khanh Hung
Journal:  Eur J Orthop Surg Traumatol       Date:  2022-07-02

2.  Prosthetic joint infection of the hip and knee due to Mycobacterium species: A systematic review.

Authors:  Asep Santoso; Krisna Yuarno Phatama; Sholahuddin Rhatomy; Nicolaas Cyrillus Budhiparama
Journal:  World J Orthop       Date:  2022-05-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.